Cargando…

Development of PD3 and PD3-B for PDEδ inhibition to modulate KRAS activity

Despite extensive efforts over 40 years, few effective KRAS inhibitors have been developed to date, mainly due to the undruggable features of KRAS proteins. In addition to the direct approach to KRAS via covalent inhibition, modulation of the prenyl-binding protein PDEδ that binds with farnesylated...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Jungeun, Lee, Ho Jin, Lee, Yeongcheol, Lim, Bumhee, Gam, Jongsik, Oh, Dong-Chan, Lee, Jeeyeon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2022
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9225715/ https://www.ncbi.nlm.nih.gov/pubmed/35695156 http://dx.doi.org/10.1080/14756366.2022.2086865

Ejemplares similares

EPHA2 feedback activation limits the response to PDEδ inhibition in KRAS-dependent cancer cells
por: Chen, Yue-hong, et al.
Publicado: (2019)

PDEδ inhibition impedes the proliferation and survival of human colorectal cancer cell lines harboring oncogenic KRas
por: Klein, Christian H., et al.
Publicado: (2018)

A Peptoid-Based Fluorescent Sensor for Cyanide Detection
por: Lim, Bumhee, et al.
Publicado: (2016)

Immune profiles according to EGFR mutant subtypes and correlation with PD-1/PD-L1 inhibitor therapies in lung adenocarcinoma
por: Koh, Young Wha, et al.
Publicado: (2023)

Identification of pyrazolopyridazinones as PDEδ inhibitors
por: Papke, Björn, et al.
Publicado: (2016)

Discovery of novel KRAS‒PDEδ inhibitors with potent activity in patient-derived human pancreatic tumor xenograft models
por: Chen, Long, et al.
Publicado: (2022)

Melatonin Downregulates PD-L1 Expression and Modulates Tumor Immunity in KRAS-Mutant Non-Small Cell Lung Cancer
por: Chao, Yi-Chun, et al.
Publicado: (2021)

The small organic molecule C19 binds and strengthens the KRAS4b-PDEδ complex and inhibits growth of colorectal cancer cells in vitro and in vivo
por: Cruz-Nova, Pedro, et al.
Publicado: (2018)

Specific inhibition of PI3Kδ/γ enhances the efficacy of anti-PD1 against osteosarcoma cancer
por: Shi, Xinge, et al.
Publicado: (2018)

Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab
por: Lee, Hyun Tae, et al.
Publicado: (2017)

Modulation of Morphology and Optical Property of Multi-Metallic PdAuAg and PdAg Alloy Nanostructures
por: Pandey, Puran, et al.
Publicado: (2018)

KRas4B-PDE6δ complex stabilization by small molecules obtained by virtual screening affects Ras signaling in pancreatic cancer
por: Casique-Aguirre, Diana, et al.
Publicado: (2018)

Significance of druggable targets (PD-L1, KRAS, BRAF, PIK3CA, MSI, and HPV) on curatively resected esophageal squamous cell carcinoma
por: Lee, Hong Kyu, et al.
Publicado: (2020)

Inhibition of PI3Kδ Differentially Regulates Poly I:C– and Human Metapneumovirus–Induced PD–L1 and PD–L2 Expression in Human Bronchial Epithelial Cells
por: Ogawa, Tomohiro, et al.
Publicado: (2021)

Statins Decrease Programmed Death-Ligand 1 (PD-L1) by Inhibiting AKT and β-Catenin Signaling
por: Lim, Woo-Jin, et al.
Publicado: (2021)

Novel C6-substituted 1,3,4-oxadiazinones as potential anti-cancer agents
por: Alam, Md. Maqusood, et al.
Publicado: (2015)

Resistance to anti-PD-1/anti-PD-L1: galectin-3 inhibition with GB1211 reverses galectin-3-induced blockade of pembrolizumab and atezolizumab binding to PD-1/PD-L1
por: Mabbitt, Joseph, et al.
Publicado: (2023)

PK/PD Modeling of the PDE7 Inhibitor—GRMS-55 in a Mouse Model of Autoimmune Hepatitis
por: Świerczek, Artur, et al.
Publicado: (2021)

The impact of single agent PD-1 or PD-L1 inhibition on advanced endometrial cancers: meta-analysis
por: Kok, P.-S., et al.
Publicado: (2022)

Response to PD1 inhibition in conventional chondrosarcoma
por: Wagner, Michael J., et al.
Publicado: (2018)

Blockade of PD-L1/PD-1 signaling promotes osteo-/odontogenic differentiation through Ras activation
por: Jeon, So Mi, et al.
Publicado: (2022)

The Chemistry of Cu(3)N and Cu(3)PdN Nanocrystals
por: Parvizian, Mahsa, et al.
Publicado: (2022)

EGFR or HER2 inhibition modulates the tumor microenvironment by suppression of PD-L1 and cytokines release
por: Suh, Koung Jin, et al.
Publicado: (2017)

WNK3 inhibition elicits antitumor immunity by suppressing PD-L1 expression on tumor cells and activating T-cell function
por: Yoon, Hyun Ju, et al.
Publicado: (2022)

Development of a PDEδ‐Targeting PROTACs that Impair Lipid Metabolism
por: Winzker, Michael, et al.
Publicado: (2020)

Currently Used Laboratory Methodologies for Assays Detecting PD-1, PD-L1, PD-L2 and Soluble PD-L1 in Patients with Metastatic Breast Cancer
por: Jeong, Seri, et al.
Publicado: (2021)

KRAS acting through ERK signaling stabilizes PD-L1 via inhibiting autophagy pathway in intrahepatic cholangiocarcinoma
por: Gao, Zheng, et al.
Publicado: (2022)

Cancer immune evasion through KRAS and PD-L1 and potential therapeutic interventions
por: Watterson, Alex, et al.
Publicado: (2023)

The reactions $pd \to ^{3}He\eta$ and $pd \to ^{3}He\pi^{+}\pi^{-}$ near the $\eta$ threshold
por: Mayer, B, et al.
Publicado: (1995)

Primary Resistance to Immune Checkpoint Blockade in an STK11/TP53/KRAS-Mutant Lung Adenocarcinoma with High PD-L1 Expression
por: Kwack, Won Gun, et al.
Publicado: (2020)

PD-L1, PD-1, LAG-3, and TIM-3 in Melanoma: Expression in Brain Metastases Compared to Corresponding Extracranial Tumors
por: Wang, Jaeyun Jane, et al.
Publicado: (2019)

Identification of cancer cytotoxic modulators of PDE3A by predictive chemogenomics
por: de Waal, Luc, et al.
Publicado: (2015)

The Impact of PD-L1 Expression in Patients with Metastatic GEP-NETs
por: Kim, Seung Tae, et al.
Publicado: (2016)

Clinicopathologic implication of PD-L1 and phosphorylated STAT3 expression in diffuse large B cell lymphoma
por: Kwon, Hyun Jung, et al.
Publicado: (2018)

PK/PD studies on non-selective PDE inhibitors in rats using cAMP as a marker of pharmacological response
por: Świerczek, Artur, et al.
Publicado: (2017)

Kaempferol and Its Glycoside, Kaempferol 7-O-rhamnoside, Inhibit PD-1/PD-L1 Interaction In Vitro
por: Kim, Ji Hye, et al.
Publicado: (2020)

PDE3 is the major cGMP-PDE in adult mouse ventricular cardiomyocytes
por: Götz, Konrad R, et al.
Publicado: (2013)

Effects of chlorinated Pd precursors and preparation methods on properties and activity of Pd/TiO(2) catalysts
por: Kim, Ye Eun, et al.
Publicado: (2020)

NIH3T3 Directs Memory-Fated CTL Programming and Represses High Expression of PD-1 on Antitumor CTLs
por: Qin, Yingyu, et al.
Publicado: (2019)

Molecular Interactions of Antibody Drugs Targeting PD-1, PD-L1, and CTLA-4 in Immuno-Oncology
por: Lee, Hyun Tae, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_c1a987hgj7cigq6vk7d5flgej5